Product Information
BUPRENORPHINE 20 MCG/HR PATCH is a generic product labeled by Alvogen Inc., priced at $58.8288 per EA under NDC 47781040804. Its NADAC has been published 204 times since Nov 9, 2022.
FDA first approved this application on May 17, 2022. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
20 ug/h
Manufacturer
Alvogen Inc.NDC
47781040804
Classification
Generic
Dosage Form
PATCH, EXTENDED RELEASE
Route
TRANSDERMAL
Effective Date
9/23/2026
Active Ingredients
BUPRENORPHINEApproval Type
Generic (ANDA)
FDA Application
ANDA207490FDA Approved
5/17/2022
TE Code
AB
On Market Since
5/17/2022
Pharmacological Classes
Price Statistics
The NADAC for BUPRENORPHINE 20 MCG/HR PATCH has been published 204 times since Nov 9, 2022, and over the history we have for it it has declined 37.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $58.8288 per EA |
|---|---|
| All-time high | $100.2806 (Feb 15, 2023) |
| All-time low | $42.3325 (Jul 17, 2024) |
| 52-week high | $58.8288 |
| 52-week low | $52.6588 |
| Median price | $58.4075 |
| Average price | $66.0539 |
| Largest weekly change | +51.6% (Aug 21, 2024) |
| Weeks tracked | 204 |
| Tracking since | Nov 9, 2022 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Alvogen Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
buprenorphine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Partial Opioid Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of BUPRENORPHINE 20 MCG/HR PATCH?
The current National Average Drug Acquisition Cost (NADAC) for BUPRENORPHINE 20 MCG/HR PATCH, manufactured by Alvogen Inc., is $58.8288 per EA (NDC 47781040804), effective Sep 30, 2026.
How has the price of BUPRENORPHINE 20 MCG/HR PATCH changed over time?
Over the history we have for it, the NADAC for BUPRENORPHINE 20 MCG/HR PATCH has declined 37.8%. It has been tracked across 204 weekly CMS publications since Nov 9, 2022.
What are the highest and lowest recorded NADAC prices for BUPRENORPHINE 20 MCG/HR PATCH?
Since Nov 9, 2022, the NADAC for BUPRENORPHINE 20 MCG/HR PATCH has ranged from a low of $42.3325 (Jul 17, 2024) to a high of $100.2806 (Feb 15, 2023), with a median of $58.4075 per EA.
Are there cheaper alternatives to BUPRENORPHINE 20 MCG/HR PATCH?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as BUPRENORPHINE 20 MCG/HR PATCH in a comparable dosage form, but none are currently priced below it.
Who manufactures BUPRENORPHINE 20 MCG/HR PATCH?
BUPRENORPHINE 20 MCG/HR PATCH (NDC 47781040804) is labeled by Alvogen Inc., and CMS classifies it as a generic product.